Sensei Biotherapeutics, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	8-K	10-K	10-K	10-K	S-1/A
Revenues	30.4	0.0	0.0	8.4	8.2
Revenue growth			-100.0%	1.5%
Cost of goods sold	50.2	0.0	0.0	16.7	12.7
Gross profit	-19.8	0.0	0.0	-8.4	-4.5
Gross margin	-65.2%			-100.0%	-54.9%
Selling, general and administrative [+]	19.8	15.8	7.5	4.1	4.5
General and administrative	19.8	15.8	7.5	4.1	4.5
Research and development		21.7	11.2
Other operating expenses	10.6	0.0			3.7
EBITDA [+]		-36.8	-18.5	-12.4	-12.7
EBITDA growth	36.4%	98.9%	49.7%	-2.6%
EBITDA margin	-165.2%			-148.0%	-154.3%
Depreciation and amortization		0.7	0.2	0.1	0.0
EBIT [+]	-50.2	-37.5	-18.7	-12.4	-12.7
EBIT growth	33.9%	100.3%	50.5%	-2.4%
EBIT margin	-165.2%			-148.9%	-154.9%
Non-recurring items [+]		0.0	0.7
Loss (gain) on sale of assets		0.0
In-process research & development			0.7
Interest expense, net [+]		-0.1	1.7
Interest expense		0.7	1.7
Interest income		0.8
Other income (expense), net [+]	1.6	0.6	1.0	-4.3	-0.3
Gain (loss) on debt retirement		0.6	0.0	-0.1
Other				0.0	0.0
Pre-tax income	-48.6	-36.8	-20.1	-16.7	-13.0
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-48.6	-36.8	-20.2	0.0	0.0
Net margin	-159.9%			-0.2%	-0.2%

Basic EPS [+]	($1.58)	($1.33)	($12.53)	($55.92)	($45.87)
Growth	19.2%	-89.4%	-77.6%	21.9%
Diluted EPS [+]	($1.58)	($1.33)	($12.53)	($55.92)	($45.87)
Growth	19.2%	-89.4%	-77.6%	21.9%

Shares outstanding (basic) [+]	30.7	27.7	1.6	0.0	0.0
Growth	10.8%	1618.9%	438745.9%	0.0%
Shares outstanding (diluted) [+]	30.7	27.7	1.6	0.0	0.0
Growth	10.8%	1618.9%	438745.9%	0.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.